en · de · es · fr · pt
faq-desk.peptides6155.com › News › Sr9009 Background And Mechanism — What the Evidence Shows

Sr9009 Background And Mechanism — What the Evidence Shows

By Editorial Desk · published 2026-04-23 · last reviewed 2026-05-14 · News

The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-05-14 and is reviewed periodically as new material appears.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Handling, Analysis, and Regulation

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small-molecule REV-ERB agonistNot a hormone or natural product
Primary targetsREV-ERBα and REV-ERBβNuclear receptors involved in circadian and metabolic regulation
AppearanceWhite to off-white solidTypical for purified research samples
SolubilitySoluble in DMSO and ethanol; low water solubilityLaboratory solubility depends on solvent and purity
Common synonymsSR9009; StenabolicStenabolic is a colloquial name, not a formal chemical name

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Related pages on this site

SR9009 Handling and Quality Control

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

Background and Receptor Mechanism

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Further detail

During the development of Half-Life 2, Newell spent months developing Steam, a digital distribution service for games. By 2011, Steam controlled between 50% and 70% of the market for downloaded PC games and generated most of Valve's revenue. At a technology conference in Seattle that year, Newell argued that software piracy was best addressed by offering a superior option rather than pursuing anti-piracy technology. He cited Steam's success in Russia, where piracy is rife, as an example. Following the difficult development of Half-Life 2, Newell said he became "obsessed" with improving Valve's work-life balance.In 2007, Newell expressed his displeasure over developing for game consoles, saying that developing processes for Sony's PlayStation 3 was a "waste of everybody's time". On stage at Sony's keynote at E3 2010, he acknowledged his criticism but discussed the open nature of the PlayStation 3 and announced a port of Portal 2, remarking that with Steamworks support it would be the best version for any console. Newell also criticized the Xbox Live service, referring to it as a "train wreck", and Windows 8, calling it a threat to the open nature of PC gaming. At the 2013 LinuxCon, Newell said the Linux operating system and open source development were "the future of gaming". He accused the proprietary systems of companies such as Microsoft and Apple of stifling innovation through slow certification processes.

Lambda denotes the failure rate of devices and systems in reliability theory, and it is measured in failure events per hour. Numerically, this lambda is also the reciprocal of the mean time between failures. In criminology, lambda denotes an individual's frequency of offences. In electrochemistry, lambda also denotes the ionic conductance of a given ion (the composition of the ion is generally shown as a subscript to the lambda character). In neurobiology, lambda denotes the length constant (or exponential rate of decay) of the electric potential across the cell membrane along a length of a nerve cell's axon. In the science and technology of heat transfer, lambda denotes the heat of vaporization per mole of material (a.k.a. its "latent heat"). In the technology and science of celestial navigation, lambda denotes the longitude as opposed to the Roman letter "L", which denotes the latitude. A block style lambda is used as a recurring symbol in the Valve computer game series Half-Life, referring to the Lambda Complex of the fictional Black Mesa Research Facility, as well as making appearances in the sequel Half-Life 2, and its subsequent prequel Half-Life: Alyx as an in-universe symbol of resistance. It is also the representation of an arm holding a crowbar, the iconic melee weapon of the series. In 1970, a lowercase lambda was chosen by Tom Doerr as the symbol of the New York chapter of the Gay Activists Alliance.

==== Orinoco River exploration ==== Humboldt’s expedition to the Upper Orinoco and the Casiquiare canal began at 4 a.m. on March 30, 1800, departing from San Fernando de Apure. The transition from the dry Llanos to the river marked a significant environmental change. The team, which included Don Nicolas Sotto, four Native rowers, and a pilot, traveled in a large sailing canoe outfitted with a cabin made of leaves and ox-hide benches. The river’s dense forests replaced the open horizons of the plains, and travel became more constrained. Wildlife was abundant, with numerous birds, capybaras, river dolphins, tapirs, peccaries, and alligators observed along the riverbanks, as well as piranhas and stingrays in the water. Humboldt noted the intensity of insect life, particularly at midday.

=== Cancer therapy === Experimental studies indicate that macrophages can affect all therapeutic modalities, including surgery, chemotherapy, radiotherapy, immunotherapy and targeted therapy. Macrophages can influence treatment outcomes both positively and negatively. Macrophages can be protective in different ways: they can remove dead tumor cells (in a process called phagocytosis) following treatments that kill these cells; they can serve as drug depots for some anticancer drugs; they can also be activated by some therapies to promote antitumor immunity. Macrophages can also be deleterious in several ways: for example they can suppress various chemotherapies, radiotherapies and immunotherapies. Because macrophages can regulate tumor progression, therapeutic strategies to reduce the number of these cells, or to manipulate their phenotypes, are currently being tested in cancer patients. However, macrophages are also involved in antibody mediated cytotoxicity (ADCC) and this mechanism has been proposed to be important for certain cancer immunotherapy antibodies. Similarly, studies identified macrophages genetically engineered to express chimeric antigen receptors as promising therapeutic approach to lowering tumor burden.

=== Creatinine clearance CCr === One method of determining GFR from creatinine is to collect urine (usually for 24 h) to determine the amount of creatinine that was removed from the blood over a given time interval. If one removes 1440 mg in 24 h, this is equivalent to removing 1 mg/min. If the blood concentration is 0.01 mg/mL (1 mg/dL), then one can say that 100 mL/min of blood is being "cleared" of creatinine, since, to get 1 mg of creatinine, 100 mL of blood containing 0.01 mg/mL would need to have been cleared. Creatinine clearance (CCr) is calculated from the creatinine concentration in the collected urine sample (UCr), urine flow rate (Vdt), and the plasma concentration (PCr). Since the product of urine concentration and urine flow rate yields creatinine excretion rate, which is the rate of removal from the blood, creatinine clearance is calculated as removal rate per min (UCr×Vdt) divided by the plasma creatinine concentration. This is commonly represented mathematically as

Sources: en.wikipedia.org

Supporting material

Gender inequalities in France affect several areas, including family life, education, employment, health, and political participation. The United Nations Development Programme (UNDP) monitors gender disparities through the Gender Inequality Index (GII), which evaluates reproductive health, empowerment, and labor market participation.

The Hitachi 917 is an automated biochemistry analyser utilised at medical laboratories to process biological fluid specimens, such as urine, cerebrospinal fluid, and most commonly, blood. Manufactured by Boehringer Mannheim, the Hitachi 917 is a commonly used routine chemical bichromatic analyser. Capable of doing 1200 test/hour with ISE, it is a popular choice among small to medium size laboratories.

Alexandra Lynn Medlin, Personal Assistant to British High Commissioner, Cape Town. Ian Adie Murray. For services to education in Murree, Pakistan. Ng Shui-Lai, . For services to welfare, Hong Kong. Edward George Pryor, , Principal Government Town Planner, Hong Kong. Olivia Margaret, Lady Roseveare. For services to education in Malawi Tatica Ernestine Scatliffe. For services to nursing and voluntary work in British Virgin Islands. Leonard Scott, lately Adviser on English Language, European Commission. Josephine Chang Siao Fong-fong. For services to the performing arts, Hong Kong. Neville Maxwell Alexander Smith, lately Chief Immigration Officer, Bermuda. Robert Soto. For services to Scuba diving, British Virgin Islands Edith Margaret Stewart, Matron, Bangkok Nursing Home, Thailand. Heather Themistocleous, Headmistress, Junior (Anglo-Cypriot) School, Nicosia. David Straiten Thomson. For welfare services to the community, Kenya. Valerie Ann Treitlein, Honorary British Consul, Conakry. Carlye Wai-Ling Tsui, . For services to the community, Hong Kong. Valentine Thomas Tudball. For services to the British community in Beirut. Michael Julian Christopher Waters, Deputy Political Adviser, Hong Kong. John Anthony Weaver. For services to the Anglican community, Sliema, Malta. The Reverend Colin Andrew Westmarland. For services to the Church of Scotland, Malta. Henry Winston Willans. For services to the British community, Uruguay. Angela Cheung Wong Wan Yiu, JP. For services to education and hospital administration, Hong Kong. Sister Annie Margaret Wong Kam-lin, Principal, St.

In any case, the levels of most steroid hormones, including testosterone and cortisol, are usually unchanged by spironolactone in humans, which may in part be related to compensatory upregulation of their synthesis. The weak steroidogenesis inhibition of spironolactone might contribute to its antiandrogenic efficacy to some degree and may explain its side effect of menstrual irregularities in women. However, its androgen synthesis inhibition is probably clinically insignificant. Spironolactone has been found in some studies to increase levels of estradiol, an estrogen, although many other studies have found no changes in estradiol levels. The mechanism of how spironolactone increases estradiol levels is unclear, but it may involve inhibition of the inactivation of estradiol into estrone and enhancement of the peripheral conversion of testosterone into estradiol. It is notable that spironolactone has been found in vitro to act as a weak inhibitor of 17β-hydroxysteroid dehydrogenase 2, an enzyme that is involved in the conversion of estradiol into estrone. Increased levels of estradiol with spironolactone may be involved in its preservation of bone density and in its side effects such as breast tenderness, breast enlargement, and gynecomastia in women and men. In response to the antimineralocorticoid activity spironolactone, and in an attempt to maintain homeostasis, the body increases aldosterone production in the adrenal cortex. Some studies have found that levels of cortisol, a glucocorticoid hormone that is also produced in the adrenal cortex, are increased as well.

Sources: en.wikipedia.org

Supporting material

GlcA = β-D-glucuronic acid, IdoA = α-L-iduronic acid, IdoA(2S) = 2-O-sulfo-α-L-iduronic acid, GlcNAc = 2-deoxy-2-acetamido-α-D-glucopyranosyl, GlcNS = 2-deoxy-2-sulfamido-α-D-glucopyranosyl, GlcNS(6S) = 2-deoxy-2-sulfamido-α-D-glucopyranosyl-6-O-sulfate One unit of heparin (the "Howell unit") is an amount approximately equivalent to 0.002 mg of pure heparin, which is the quantity required to keep 1 ml of cat's blood fluid for 24 hours at 0 °C.

== PNA translation from other nucleic acids == Several labs have reported sequence-specific polymerization of peptide nucleic acids from DNA or RNA templates. Liu and coworkers used these polymerization methods to evolve functional PNAs with the ability to fold into three-dimensional structures, similar to proteins, aptamers and ribozymes.

== Adverse effects == The adverse effects of pethidine administration are primarily those of the opioids as a class: nausea, vomiting, dizziness, diaphoresis, urinary retention, and constipation. Due to moderate stimulant effects mediated by pethidine's dopamine and norepinephrine reuptake inhibition, sedation is less likely compared to other opioids. Unlike other opioids, it does not cause miosis because of its anticholinergic properties. Overdose can cause muscle flaccidity, respiratory depression, obtundation, psychosis, cold and clammy skin, hypotension, and coma. A narcotic antagonist such as naloxone is indicated to reverse respiratory depression and other effects of pethidine. Serotonin syndrome has occurred in patients receiving concurrent antidepressant therapy with selective serotonin reuptake inhibitors (SSRIs) or monoamine oxidase inhibitors, or other medication types (see Interactions below). Convulsive seizures sometimes observed in patients receiving parenteral pethidine on a chronic basis have been attributed to accumulation in plasma of the metabolite norpethidine (normeperidine). Fatalities have occurred following either oral or intravenous pethidine overdose.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

How does SR9009 work?

It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.

Is SR9009 proven to improve human performance?

No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.

Network